Asia-Pacific Peripheral Neuropathy Treatment Market is estimated to grow at a CAGR of 5.1% during the forecast period. A significant rise in cancer prevalence is one of the major factors accelerating the demand for peripheral neuropathy treatment in the region. As per the World Health Organization (WHO), the number of new cancer incidences in China was nearly 4.3 million in 2018. Additionally, the number of new cancer incidences in India was nearly 1.1 million in 2018. Chemotherapy is most often used for cancer treatment, which is significantly associated with the risk of developing chemotherapy-induced peripheral neuropathy (CIPN). Chemotherapy is used to destroy rapidly growing cancer cells in the body. The condition has been anticipated to be high in patients who received treatment with any neurotoxic chemotherapeutic agent. CIPN is normally treated with anticonvulsants, analgesics, and antidepressants. Topical agents including lidocaine are often used, and opioids can also be used in cases that involve extreme pain.
A full report of Asia-Pacific Peripheral Neuropathy Treatment Market is available at: https://www.omrglobal.com/industry-reports/asia-pacific-peripheral-neuropathy-treatment-market
Scope of the Asia-Pacific Peripheral Neuropathy Treatment Market
Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and Application
- Countries Covered- China, India, Japan, and Rest of Asia-Pacific
- Competitive Landscape- Alembic Pharmaceuticals Ltd., Cipla Ltd., Daiichi Sankyo Company, Ltd., and Pfizer Inc.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-peripheral-neuropathy-treatment-market
Recent Strategic Initiatives in the Asia-Pacific Peripheral Neuropathy Treatment Market
- In April 2019, Daiichi Sankyo Company, Ltd. declared the launch of Tarlige tablets for pain treatment in Japan. In Japan 2019, ?2? ligand drug was approved in Japan for marketing based on phase 3 clinical trials results performed in Asia, for patients suffering from diabetic peripheral neuropathic pain, postherpetic neuralgia (PHN), for the treatment of peripheral neuropathic pain.
- In July 2019, Cipla declared that InvaGen Pharmaceuticals, its subsidiary gained US approval for Pregabalin Capsules, which is intended for neuropathic pain management associated with some illnesses. InvaGen gained approval from the US FDA for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg.
Key questions addressed by the report
- What is the market growth rate?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected region/segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Asia-Pacific Peripheral Neuropathy Treatment Market-Segmentation
By Type
- Antidepressants
- Pain Relievers
- Antiseizure
- Others
By Application
- Diabetes
- Chemotherapy-Induced
- Others
Asia-Pacific Peripheral Neuropathy Treatment Market– Segment by Region
- China
- Japan
- India
- Rest of Asia-Pacific
Company Profiles
- Alembic Pharmaceuticals Ltd.
- Bristol Myers Squibb Co.
- Cipla Ltd.
- Daiichi Sankyo Company, Ltd.
- Eli Lilly and Co.
- Glenmark Pharmaceuticals Ltd.
- Lupin, Ltd.
- Mylan N.V.
- Novartis International AG
- Pfizer, Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
